SCHEMBL27229751

SCHEMBL27229751

OCCCC1(CO)CC(OCc2ccccc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40
OPRM1 P35372 3/20 0.40
OPRL1 P41146 3/20 0.40
DPP4 P27487 1/20 0.40
SIGMAR1 Q99720 2/20 0.38
TMEM97 Q5BJF2 1/20 0.38
CARM1 Q86X55 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
PRMT8 Q9NR22 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
EPHX2 P34913 2/20 0.38
LTA4H P09960 1/20 0.38
BCHE P06276 3/20 0.38
PDPK1 O15530 1/20 0.35
MTOR P42345 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8345616 0.88 CTSL (0.46) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL8053071 0.82 DPP4 (0.51) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL27229827 0.79 OPRM1 (0.34) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL3818209 0.78 OPRM1 (0.47) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL22501954 0.78 CTSL (0.44) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL27229703 0.78 BCHE (0.40) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL22029580 0.78 CARM1 (0.46) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL20621138 0.76 CTSL (0.45) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL25183679 0.76 CTSL (0.47) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL18544430 0.75 DPP4 (0.47) CTSLCTSBCTSKOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2024-05-30 US disclosed
WO-2022169985-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC5 CTSL 3427/4885CTSB 534/4885CTSK 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.